Clinical Trials Logo

Clinical Trial Summary

Phase II:To explore the optimal effective dose of SHR7280 tablets in subjects with menorrhagia with uterine fibroids as a phase III treatment dose. Phase III:To evaluate the efficacy of the selected dose of SHR7280 compared with placebo in reducing menstrual bleeding in subjects with menorrhagic uterine fibroids in phase II studies.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05442827
Study type Interventional
Source Jiangsu HengRui Medicine Co., Ltd.
Contact Zhenyi Zhu
Phone 0518-82342973
Email zhenyi.zhu@hengrui.com
Status Recruiting
Phase Phase 2/Phase 3
Start date September 10, 2022
Completion date June 1, 2026